Lisuride maleate is a non-selective dopamine agonist and G-protein-biased 5-HT2A receptor agonist capable of blocking prolactin release. Lisuride maleate may be employed in studies of Parkinson's disease, depression, and hyperprolactinemia disorders.

Lisuride maleate, at doses of 0.78 mg/kg (intraperitoneal injection) and 3.13 mg/kg (oral administration), exhibits a potency that is 3-4 times higher when administered intraperitoneally compared to oral administration [3]. When administered intraperitoneally (ip) at doses ranging from 0.78 to 3.13 mg/kg, Lisuride maleate effectively antagonizes the motor inhibition and hypothermia induced by reserpine [3]. The effects of Lisuride maleate (0.78-3.13 mg/kg, intraperitoneal injection) are similar to those of apomorphine and D-amphetamine, and it can induce significant hypothermia at doses as low as 0.10 mg/kg [3].